Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.23)
# 2,815
Out of 5,040 analysts
114
Total ratings
38.24%
Success rate
-0.42%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI Atai Life Sciences | Maintains: Buy | $11 → $14 | $5.55 | +152.25% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.02 | +741.58% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $8.15 | +489.32% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $6.24 | +140.38% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $7.08 | +281.36% | 6 | Jul 29, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $6.00 | +1,066.67% | 8 | Jul 8, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $143.67 | +11.37% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $150.08 | +46.59% | 21 | May 2, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $10.68 | +134.08% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $4.55 | +163.74% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $2.26 | +3,439.82% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $13.27 | +111.00% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $12.47 | +12.27% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $31.69 | -36.89% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $21.73 | +51.86% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $16.30 | +820.25% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $19.02 | - | 2 | Jan 31, 2017 |
Atai Life Sciences
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $5.55
Upside: +152.25%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.02
Upside: +741.58%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $8.15
Upside: +489.32%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $6.24
Upside: +140.38%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $7.08
Upside: +281.36%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $6.00
Upside: +1,066.67%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $143.67
Upside: +11.37%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $150.08
Upside: +46.59%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $10.68
Upside: +134.08%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.55
Upside: +163.74%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.26
Upside: +3,439.82%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $13.27
Upside: +111.00%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $12.47
Upside: +12.27%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $31.69
Upside: -36.89%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $21.73
Upside: +51.86%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $16.30
Upside: +820.25%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $19.02
Upside: -